These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 25894261)

  • 21. Beyond glycemic control: treating the entire type 2 diabetes disorder.
    Brunton S
    Postgrad Med; 2009 Sep; 121(5):68-81. PubMed ID: 19820276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Potential of a GLP-1 receptor agonist combined with basal insulin in the treatment of type 2 diabetes].
    Scheen AJ; Paquot N
    Rev Med Suisse; 2014 Aug; 10(439):1549-54. PubMed ID: 25272672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: a population-based cohort analysis.
    Driessen JH; Henry RM; van Onzenoort HA; Lalmohamed A; Burden AM; Prieto-Alhambra D; Neef C; Leufkens HG; de Vries F
    Calcif Tissue Int; 2015 Aug; 97(2):104-12. PubMed ID: 25894068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
    Seufert J; Gallwitz B
    Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Zhang F; Tong Y; Su N; Li Y; Tang L; Huang L; Tong N
    J Diabetes; 2015 May; 7(3):329-39. PubMed ID: 25043423
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of genetic variation in the cannabinoid receptor gene (CNR1) (G1359A polymorphism) on weight loss and cardiovascular risk factors after liraglutide treatment in obese patients with diabetes mellitus type 2.
    de Luis DA; Ovalle HF; Soto GD; Izaola O; de la Fuente B; Romero E
    J Investig Med; 2014 Feb; 62(2):324-7. PubMed ID: 24322329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic intervention in the GLP-1 pathway in Type 2 diabetes.
    Levy JC
    Diabet Med; 2006 Mar; 23 Suppl 1():14-9. PubMed ID: 16483260
    [No Abstract]   [Full Text] [Related]  

  • 28. The glucagon-like peptide-1 receptor--or not?
    Pyke C; Knudsen LB
    Endocrinology; 2013 Jan; 154(1):4-8. PubMed ID: 23267050
    [No Abstract]   [Full Text] [Related]  

  • 29. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON).
    Mathieu C; Rodbard HW; Cariou B; Handelsman Y; Philis-Tsimikas A; Ocampo Francisco AM; Rana A; Zinman B;
    Diabetes Obes Metab; 2014 Jul; 16(7):636-44. PubMed ID: 24443830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.
    Madsbad S; Krarup T; Deacon CF; Holst JJ
    Curr Opin Clin Nutr Metab Care; 2008 Jul; 11(4):491-9. PubMed ID: 18542012
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical pearls for initiating and utilizing liraglutide in patients with type 2 diabetes.
    Gross B
    J Pharm Pract; 2013 Apr; 26(2):144-50. PubMed ID: 23204146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?
    Peterson G
    Ann Med; 2012 Jun; 44(4):338-49. PubMed ID: 22530845
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.
    Moon HS; Kim MK; Son MH
    Arch Pharm Res; 2011 Jul; 34(7):1041-3. PubMed ID: 21811909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Glucagon-like peptide-1 receptor agonists].
    Kurose T; Seino Y
    Nihon Rinsho; 2012 May; 70 Suppl 3():689-92. PubMed ID: 22768599
    [No Abstract]   [Full Text] [Related]  

  • 36. Glucagon-Like Peptide-1 Formulation--the Present and Future Development in Diabetes Treatment.
    Lee CY
    Basic Clin Pharmacol Toxicol; 2016 Mar; 118(3):173-80. PubMed ID: 26551045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Physiologic and weight-focused treatment strategies for managing type 2 diabetes mellitus: the metformin, glucagon-like peptide-1 receptor agonist, and insulin (MGI) approach.
    Nadeau DA
    Postgrad Med; 2013 May; 125(3):112-26. PubMed ID: 23748512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GLP-1 receptor agonists: effects on cardiovascular risk reduction.
    Lorber D
    Cardiovasc Ther; 2013 Aug; 31(4):238-49. PubMed ID: 23865382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Weight beneficial treatments for type 2 diabetes.
    Meneghini LF; Orozco-Beltran D; Khunti K; Caputo S; Damçi T; Liebl A; Ross SA
    J Clin Endocrinol Metab; 2011 Nov; 96(11):3337-53. PubMed ID: 21900381
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liraglutide: a review of its use in adult patients with type 2 diabetes mellitus.
    Scott LJ
    Drugs; 2014 Dec; 74(18):2161-74. PubMed ID: 25367717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.